Proguanil
Antimalarial — ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
Also known as: chloroguanide, chloroguanide HCl, chloroguanide hydrochloride, proguanil HCl, proguanil hydrochloride
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Proguanil is an ofp drug in the Antimalarial class catalogued in DrugCentral. It was first approved by the FDA in 2000. Its mechanism of action is classified as Dihydrofolate Reductase Inhibitors. DrugCentral lists 4 molecular targets, including Taar1, Bifunctional dihydrofolate reductase-thymidylate synthase and Bifunctional dihydrofolate reductase-thymidylate synthase. Recorded indications include Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention, Falciparum malaria and Plasmodium Falciparum Malaria Prevention.
- Approval status: ofp (first approved 2000 by the FDA).
- Drug class: Antimalarial.
- Mechanism of action: Dihydrofolate Reductase Inhibitors.
- Molecular targets: Taar1, Bifunctional dihydrofolate reductase-thymidylate synthase, Bifunctional dihydrofolate reductase-thymidylate synthase and Bifunctional dihydrofolate reductase-thymidylate synthase (4 listed in DrugCentral).
- Indications: Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention, Falciparum malaria and Plasmodium Falciparum Malaria Prevention.
- ATC code: P01BB01 (Biguanides).
- Molecular formula: C11H16ClN5; molecular weight 253.73 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (3)
- Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention
- Falciparum malaria
- Plasmodium Falciparum Malaria Prevention
Off-label uses (1)
- Vivax malaria
Contraindications (8)
- Acute nephropathy
- Anemia due to enzyme deficiency
- Chronic diarrhea
- Disease of liver
- Hepatic failure
- Hyperglycemia
- Malabsorption States
- Vomiting
Mechanism & targets
| Mechanism of action (MoA) | Dihydrofolate Reductase Inhibitors |
|---|---|
| Established pharmacologic class | Antimalarial |
Molecular targets (4)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Trace amine-associated receptor 1 | Taar1 | unknown | EC50 5.27 |
| Bifunctional dihydrofolate reductase-thymidylate synthase | — | unknown | — |
| Bifunctional dihydrofolate reductase-thymidylate synthase | — | unknown | — |
| Bifunctional dihydrofolate reductase-thymidylate synthase | — | inhibitor | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2000-07-14 | FDA | — | GLAXOSMITHKLINE |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
P01BB01 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › ANTIMALARIALS › Biguanides |
P01BB51 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › ANTIMALARIALS › Biguanides |
P01BB52 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › ANTIMALARIALS › Biguanides |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Malaria | 251.2 |
| Hallucination | 59.7 |
| Psychotic disorder | 59.0 |
| Plasmodium falciparum infection | 55.2 |
| Schizophrenia | 45.9 |
| Abnormal dreams | 42.6 |
| Hypomania | 37.8 |
| Pyrexia | 37.2 |
| Exposure during pregnancy | 37.0 |
| Vomiting | 33.4 |
| Total lung capacity increased | 33.3 |
| Asthma-chronic obstructive pulmonary disease overlap syndrome | 31.0 |
Chemical structure
| Molecular formula | C11H16ClN5 |
|---|---|
| Molecular weight | 253.73 g/mol |
| CAS number | 500-92-5 |
| InChIKey | SSOLNOMRVKKSON-UHFFFAOYSA-N |
| PubChem CID | 6178111 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Proguanil used for?
DrugCentral lists the following indications for Proguanil: Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention, Falciparum malaria and Plasmodium Falciparum Malaria Prevention.
How does Proguanil work?
Proguanil is classified as Dihydrofolate Reductase Inhibitors; its molecular targets in DrugCentral include Taar1, Bifunctional dihydrofolate reductase-thymidylate synthase, Bifunctional dihydrofolate reductase-thymidylate synthase and Bifunctional dihydrofolate reductase-thymidylate synthase (inhibitor).
When was Proguanil first approved?
Proguanil was first approved by the FDA in 2000.
What drug class does Proguanil belong to?
Proguanil is in the Antimalarial class.
What is the chemical formula of Proguanil?
Proguanil has the molecular formula C11H16ClN5 and a molecular weight of 253.73 g/mol.
Browse: all drugs starting with P · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2282 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1201059 — compound record and bioactivity
- PubChem CID 6178111 — chemical identifiers
- DrugBank DB01131 — drug record
- FDA UNII S61K3P7B2V — substance identity
- DailyMed: FDA labels for Proguanil — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.